UCB - Operating Profit

Stock Price
264.50
Daily Change
-3.30 -1.23%
Monthly
4.59%
Yearly
64.44%
Q2 Forecast
257.81

UCB reported EUR1.29B in Operating Profit for its fiscal semester ending in December of 2025.





Operating Profit Change Date
Alcon AG USD 313M 19M Dec/2025
Almirall EUR 30.23M 12.8M Dec/2025
Amarin USD -2.26M 564K Dec/2025
argenx SE USD 371.14M 21.17M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Bayer EUR 1.11B 1.65B Dec/2025
Galapagos EUR 780.56M 822.23M Dec/2025
Genmab DKK 260M 199M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
GRIFOLS EUR 275.38M 76.74M Dec/2025
Hikma Pharmaceutical USD 348M 161M Dec/2025
Lonza CHF 673M 243M Jun/2025
Merck EUR 474M 738M Dec/2025
Novartis USD 4.06B 437M Dec/2025
Orion EUR 328.2M 207.2M Dec/2025
Recordati EUR 278.23M 112.58M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
UCB EUR 1.29B 571M Dec/2025
Unibail Rodamco EUR 844.1M 102.4M Dec/2025